English | ÖÐÎÄ
News

IVD China last week: Beckman Coulter and Eisai China, Illumina and OE Biotech, Adicon, Weigao

2025/11/17 9:40:14¡¡Views£º3

Beckman Coulter and Eisai China Forge Strategic Cooperation on Alzheimer's Disease Diagnosis

 

 

Leveraging their respective strengths in pharmaceutical R&D and in vitro diagnostics (IVD), both parties will build an end-to-end system covering "diagnosis ¨C treatment ¨C patient support". Core cooperation initiatives include the validation of blood testing technology, an A¦Â testing patient assistance program, and disease screening projects. The collaboration aims to break through the development bottlenecks in Alzheimer's disease diagnosis and treatment, enhance the clinical value of blood tests, promote their widespread adoption, and ultimately facilitate the implementation of the "Healthy China" strategy.

 

 

Illumina and OE Biotech Forge Strategic Cooperation on Innovative Proteomics, Positioning for New Heights in Precision Medicine

 

 

Illumina has entered into a technical cooperation with OE Biotech ¡ª on Illumina® Protein Prep (IPP) technology. The two parties will jointly promote marketing expansion, multi-omics technology integration, and establish a collaborative mechanism to collectively drive the innovation and development of proteomics and multi-omics research.

 

 

Adicon¡¯s Full Acquisition of CrownBio: Forging a Global Integrated Oncology R&D Layout

 

 

Adicon Holdings, one of China¡¯s top three Independent Clinical Laboratories (ICL) service providers, officially announced that it has signed an agreement to fully acquire CrownBio ¡ª a world-leading preclinical Contract Research Organization (CRO) ¡ª for a total consideration of approximately USD 204 million. In a subsequent conference call, Adicon¡¯s Executive Director and Chief Executive Officer stated that this move represents a significant milestone in the company¡¯s development. It will establish an integrated service platform spanning early-stage research to clinical testing, and significantly accelerate its global expansion.

 

 

Weigao's Subsidiary Establishes Joint Venture with PT Oneject Indonesia in Indonesia

 

Weigao International Holding Corporation Pte. Ltd. has entered into a joint venture agreement with PT Oneject Indonesia (the Joint Venture Partner) to establish a joint venture named Oneject Wego Medical (the Joint Venture) in Indonesia. The Joint Venture¡¯s business activities will include the manufacturing and sales of intravenous catheters, infusion sets and other medical consumables in Indonesia. It will continue to focus on localized production, with target products being those currently highly dependent on imports in Indonesia.